Sun Pharmaceutical enters into partnership with AstraZeneca Pharma India

23 Mar 2016 Evaluate

Sun Pharmaceutical Industries has entered into partnership with the AstraZeneca Pharma India for the distribution of dapagliflozin, an innovative Type 2 diabetes medicine, in India. Dapagliflozin is AstraZeneca India’s leading diabetes medicine.

Under the agreement, the company will promote and distribute dapagliflozin under the brand name ‘Oxra’. AstraZeneca India markets dapagliflozin under the brand name ‘Forxiga’ and under the terms of the agreement, both companies will promote, market & distribute dapagliflozin in India under different brand names. AstraZeneca will retain the intellectual property rights to dapagliflozin.

The company will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name ‘Oxramet’, following regulatory approval. AstraZeneca India is currently seeking approval from the Drug Controller General of India for the combination of dapagliflozin with metformin.

Sun Pharma is world's fifth largest specialty generic and India's top pharmaceutical company. With a vertically integrated business, economies of scale, an extremely skilled team enabling delivery of quality products at affordable prices and trusted by customers and patients in over 150 countries globally. The company's global presence is supported by 49 manufacturing facilities spread across 6 continents, R&D centres worldwide and a multi-cultural workforce representing more than 50 nationalities.

Sun Pharma Inds. Share Price

1612.00 -61.55 (-3.68%)
20-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.00
Dr. Reddys Lab 1166.90
Cipla 1377.85
Zydus Lifesciences 872.95
Lupin 2166.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×